Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Factors associated with endocrine therapy adherence among post-menopausal women treated for early-stage breast cancer in Ontario, Canada.

Blanchette PS, Lam M, Richard L, Allen B, Shariff SZ, Vandenberg T, Pritchard KI, Chan KKW, Louie AV, Desautels D, Raphael J, Earle CC.

Breast Cancer Res Treat. 2019 Oct 1. doi: 10.1007/s10549-019-05430-6. [Epub ahead of print]

PMID:
31571072
2.

Influenza Vaccine Effectiveness Among Patients With Cancer: A Population-Based Study Using Health Administrative and Laboratory Testing Data From Ontario, Canada.

Blanchette PS, Chung H, Pritchard KI, Earle CC, Campitelli MA, Buchan SA, Schwartz KL, Crowcroft NS, Gubbay JB, Karnauchow T, Katz K, McGeer AJ, McNally JD, Richardson DC, Richardson SE, Rosella LC, Simor A, Smieja M, Zahariadis G, Campigotto A, Kwong JC.

J Clin Oncol. 2019 Oct 20;37(30):2795-2804. doi: 10.1200/JCO.19.00354. Epub 2019 Aug 29.

PMID:
31465264
3.

Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?

Komorowski AS, Warner E, MacKay HJ, Sahgal A, Pritchard KI, Jerzak KJ.

Clin Breast Cancer. 2019 Jul 11. pii: S1526-8209(18)30863-2. doi: 10.1016/j.clbc.2019.06.007. [Epub ahead of print]

PMID:
31447286
4.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
5.

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.

Robertson JFR, Jiang Z, Di Leo A, Ohno S, Pritchard KI, Ellis M, Bradbury I, Campbell C.

Breast Cancer. 2019 May 11. doi: 10.1007/s12282-019-00973-4. [Epub ahead of print]

PMID:
31079343
6.

Cognitive effects of adjuvant endocrine therapy in older women treated for early-stage breast cancer: a 1-year longitudinal study.

Underwood EA, Jerzak KJ, Lebovic G, Rochon PA, Elser C, Pritchard KI, Tierney MC.

Support Care Cancer. 2019 Aug;27(8):3035-3043. doi: 10.1007/s00520-018-4603-5. Epub 2019 Jan 4.

PMID:
30610433
7.

Bone-Targeted Therapy in Early Breast Cancer.

Jerzak KJ, Raphael J, Desautels DN, Blanchette PS, Tyono I, Pritchard KI.

Oncology (Williston Park). 2018 Nov 15;32(11):562-9. Review.

8.

Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study.

Jerzak KJ, Cockburn JG, Dhesy-Thind SK, Pond GR, Pritchard KI, Nofech-Mozes S, Sun P, Narod SA, Bane A.

Breast Cancer Res Treat. 2018 Oct;171(3):709-717. doi: 10.1007/s10549-018-4844-5. Epub 2018 Jun 18.

PMID:
29915948
9.

Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases.

O'Reilly MA, Chinnery T, Yee ML, Wu SK, Hynynen K, Kerbel RS, Czarnota GJ, Pritchard KI, Sahgal A.

Sci Rep. 2018 Jun 13;8(1):9013. doi: 10.1038/s41598-018-27335-y.

10.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

11.

An update on treatment for post-menopausal metastatic breast cancer in elderly patients.

Menjak IB, Jerzak KJ, Desautels DN, Pritchard KI.

Expert Opin Pharmacother. 2018 Apr;19(6):597-609. doi: 10.1080/14656566.2018.1454431. Review.

PMID:
29601247
12.

Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor-Treated Patients: CCTG MA.27.

Strasser-Weippl K, Higgins MJ, Chapman JW, Ingle JN, Sledge GW, Budd GT, Ellis MJ, Pritchard KI, Clemons MJ, Badovinac-Crnjevic T, Han L, Gelmon KA, Rabaglio M, Elliott C, Shepherd LE, Goss PE.

J Natl Cancer Inst. 2018 Sep 1;110(9):1003-1008. doi: 10.1093/jnci/djy017.

13.

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.

Blanchette PS, Desautels DN, Pond GR, Bartlett JMS, Nofech-Mozes S, Yaffe MJ, Pritchard KI.

Breast Cancer Res Treat. 2018 Jul;170(1):169-177. doi: 10.1007/s10549-018-4734-x. Epub 2018 Mar 8.

PMID:
29520532
14.

Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.

Torres S, Trudeau M, Gandhi S, Warner E, Verma S, Pritchard KI, Petrella T, Hew-Shue M, Chao C, Eisen A.

Oncologist. 2018 Jul;23(7):768-775. doi: 10.1634/theoncologist.2017-0346. Epub 2018 Jan 25.

15.

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.

Raphael J, Desautels D, Pritchard KI, Petkova E, Shah PS.

Eur J Cancer. 2018 Mar;91:38-46. doi: 10.1016/j.ejca.2017.12.010. Epub 2018 Jan 11. Review.

PMID:
29331750
16.

Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years.

Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ.

J Clin Oncol. 2018 Feb 20;36(6):563-571. doi: 10.1200/JCO.2017.75.7500. Epub 2018 Jan 12. Erratum in: J Clin Oncol. 2018 May 20;36(15):1540.

17.

Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis.

Underwood EA, Rochon PA, Moineddin R, Lee PE, Wu W, Pritchard KI, Tierney MC.

Breast Cancer Res Treat. 2018 Apr;168(2):299-310. doi: 10.1007/s10549-017-4627-4. Epub 2017 Dec 20. Review.

PMID:
29264751
18.

20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF; EBCTCG.

N Engl J Med. 2017 Nov 9;377(19):1836-1846. doi: 10.1056/NEJMoa1701830.

19.

Extended adjuvant therapy: the role of subset analyses.

Pritchard KI.

Lancet Oncol. 2017 Nov;18(11):1431-1433. doi: 10.1016/S1470-2045(17)30787-8. Epub 2017 Oct 12. No abstract available.

PMID:
29031779
20.

Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis.

Raphael J, Helou J, Pritchard KI, Naimark DM.

Eur J Cancer. 2017 Nov;85:146-154. doi: 10.1016/j.ejca.2017.08.018. Epub 2017 Sep 18.

PMID:
28930692
21.

Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.

Lipton A, Chapman JW, Leitzel K, Garg A, Pritchard KI, Ingle JN, Budd GT, Ellis MJ, Sledge GW, Rabaglio M, Han L, Elliott CR, Shepherd LE, Goss PE, Ali SM.

Cancer. 2017 Jul 1;123(13):2444-2451. doi: 10.1002/cncr.30682. Epub 2017 May 2.

22.

Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.

Lohmann AE, Liebman MF, Brien W, Parulekar WR, Gelmon KA, Shepherd LE, Ligibel JA, Hershman DL, Rastogi P, Mayer IA, Hobday TJ, Lemieux J, Thompson AM, Pritchard KI, Whelan TJ, Mukherjee SD, Chalchal HI, Bernstein V, Stambolic V, Chen BE, Goodwin PJ; From the CCTG, Alliance, SWOG, ECOG, NSABP Cooperative Groups.

Breast Cancer Res Treat. 2017 Jul;164(2):371-378. doi: 10.1007/s10549-017-4265-x. Epub 2017 Apr 26.

23.

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.

Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA.

Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152.

24.

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard KI, Swain S, Wang Z, Wang Y, Whelan T, Peto R, McGale P; Early Breast Cancer Trialists’ Collaborative Group.

J Clin Oncol. 2017 May 20;35(15):1641-1649. doi: 10.1200/JCO.2016.72.0722. Epub 2017 Mar 20.

25.

Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.

Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J.

J Clin Oncol. 2017 Apr 1;35(10):1041-1048. doi: 10.1200/JCO.2016.69.2871. Epub 2017 Jan 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):359.

PMID:
28113032
26.

Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?

Rana P, Pritchard KI, Kerbel R.

Eur J Cancer. 2017 Jan;70:143-145. doi: 10.1016/j.ejca.2016.11.002. Epub 2016 Dec 2. No abstract available.

PMID:
27916568
27.

Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2- Advanced Breast Cancer.

Pritchard KI, Chia SK, Simmons C, McLeod D, Paterson A, Provencher L, Rayson D.

Oncologist. 2017 Jan;22(1):12-24. doi: 10.1634/theoncologist.2016-0185. Epub 2016 Nov 18.

28.

Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence.

Desautels DN, Blanchette PS, Pritchard KI.

Eur J Cancer. 2016 Nov;68:176-178. doi: 10.1016/j.ejca.2016.09.007. Epub 2016 Oct 21. No abstract available.

PMID:
27776294
29.

The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?

Jerzak KJ, Pritchard KI.

Eur J Cancer. 2016 Nov;68:173-175. doi: 10.1016/j.ejca.2016.08.021. Epub 2016 Oct 19. No abstract available.

PMID:
27768924
30.

Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.

Ingle JN, Xie F, Ellis MJ, Goss PE, Shepherd LE, Chapman JW, Chen BE, Kubo M, Furukawa Y, Momozawa Y, Stearns V, Pritchard KI, Barman P, Carlson EE, Goetz MP, Weinshilboum RM, Kalari KR, Wang L.

Cancer Res. 2016 Dec 1;76(23):7012-7023. Epub 2016 Oct 10.

31.

An update on adjuvant systemic therapy for elderly patients with early breast cancer.

Jerzak KJ, Desautels DN, Pritchard KI.

Expert Opin Pharmacother. 2016 Oct;17(14):1881-8. doi: 10.1080/14656566.2016.1219339. Epub 2016 Aug 19. Review.

PMID:
27539883
32.

Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies.

Lee PE, Tierney MC, Wu W, Pritchard KI, Rochon PA.

Breast Cancer Res Treat. 2016 Aug;158(3):407-20. doi: 10.1007/s10549-016-3906-9. Epub 2016 Jul 18. Review.

PMID:
27432418
33.

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.

Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR.

N Engl J Med. 2016 Jul 21;375(3):209-19. doi: 10.1056/NEJMoa1604700. Epub 2016 Jun 5.

34.

Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN.

Breast Cancer Res Treat. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z. Epub 2016 Apr 26.

PMID:
27116182
35.

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart M, Azim HA Jr.

J Natl Cancer Inst. 2016 Apr 20;108(8). pii: djw037. doi: 10.1093/jnci/djw037. Print 2016 Aug.

36.

New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole - Analyses from NCIC CTG MA.17.

Liedke PE, Tu D, Shepherd L, Chavarri-Guerra Y, Pritchard KI, Stearns V, Goss PE.

Breast. 2016 Jun;27:99-104. doi: 10.1016/j.breast.2016.02.010. Epub 2016 Apr 5.

37.

Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.

Chapman JA, Shepherd LE, Ingle JN, Muss HB, Pritchard KI, Gelmon KA, Whelan TJ, Elliott C, Goss PE.

Breast Cancer Res Treat. 2016 Apr;156(2):343-9. doi: 10.1007/s10549-016-3761-8. Epub 2016 Mar 23.

38.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
39.

Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies.

Bergh J, Pritchard KI, Cameron D.

J Clin Oncol. 2016 Mar 20;34(9):895-7. doi: 10.1200/JCO.2015.65.2255. Epub 2016 Jan 19. No abstract available.

PMID:
26786914
40.

Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study.

Sgroi DC, Chapman JA, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M.

Breast Cancer Res. 2016 Jan 4;18(1):1. doi: 10.1186/s13058-015-0660-6.

41.

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, Bordeleau L, Pritchard KI.

J Clin Oncol. 2016 Apr 1;34(10):1065-71. doi: 10.1200/JCO.2015.62.8503. Epub 2015 Nov 23.

PMID:
26598746
42.

Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, McFadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber RD, Perez EA.

J Clin Oncol. 2016 Apr 1;34(10):1034-42. doi: 10.1200/JCO.2015.62.1797. Epub 2015 Nov 23. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):356.

43.

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.

Trudeau ME, Chapman JA, Guo B, Clemons MJ, Dent RA, Jong RA, Kahn HJ, Pritchard KI, Han L, O'Brien P, Shepherd LE, Parissenti AM.

Springerplus. 2015 Oct 21;4:631. doi: 10.1186/s40064-015-1392-x. eCollection 2015.

44.

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA 3rd, Pritchard KI, Campone M, Noguchi S, Perez AT, Deleu I, Shtivelband M, Masuda N, Dakhil S, Anderson I, Robinson DM, He W, Garg A, McDonald ER 3rd, Bitter H, Huang A, Taran T, Bachelot T, Lebrun F, Lebwohl D, Baselga J.

J Clin Oncol. 2016 Feb 10;34(5):419-26. doi: 10.1200/JCO.2014.60.1971. Epub 2015 Oct 26. Erratum in: J Clin Oncol. 2019 Feb 1;37(4):354. J Clin Oncol. 2019 Feb 1;37(4):355.

45.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

46.

A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.

Spears M, Yousif F, Lyttle N, Boutros PC, Munro AF, Twelves C, Pritchard KI, Levine MN, Shepherd L, Bartlett JM.

Oncotarget. 2015 Oct 13;6(31):31693-701. doi: 10.18632/oncotarget.5562.

47.

Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.

Chapman JA, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN.

Breast Cancer Res Treat. 2015 Sep;153(2):353-60. doi: 10.1007/s10549-015-3547-4. Epub 2015 Aug 15.

48.

The effect of melatonin on sleep and quality of life in patients with advanced breast cancer.

Innominato PF, Lim AS, Palesh O, Clemons M, Trudeau M, Eisen A, Wang C, Kiss A, Pritchard KI, Bjarnason GA.

Support Care Cancer. 2016 Mar;24(3):1097-105. doi: 10.1007/s00520-015-2883-6. Epub 2015 Aug 11.

PMID:
26260726
49.

Regional Nodal Irradiation in Early-Stage Breast Cancer.

Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators.

N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340.

50.

Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis.

Wong WW, Hicks LK, Tu HA, Pritchard KI, Krahn MD, Feld JJ, Chan KK.

Breast Cancer Res Treat. 2015 Jun;151(3):639-52. doi: 10.1007/s10549-015-3382-7. Epub 2015 May 12.

PMID:
25962692

Supplemental Content

Loading ...
Support Center